Background-[Arg8]-vasopressin (AVP) activates 3 G-protein-coupled receptors: V1A, V2, and V1B. The AVP-V1A receptor is the primary AVP receptor in the heart; however, its role in cardiac homeostasis is controversial. To better understand AVP-mediated signaling in the heart, we created a transgenic mouse with controlled overexpression of the V1A receptor. Methods and Results-The V1A receptor transgene was placed under the control of the tetracycline-regulated, cardiac-specific ␣-myosin heavy chain promoter (V1A-TG). V1A-TG mice had a normal cardiac function phenotype at 10 weeks of age; however, by 24 weeks of age, tetracycline-transactivating factor/V1A-TG mouse hearts had reduced cardiac function, cardiac hypertrophy, and dilatation of the ventricular cavity. Contractile dysfunction was also observed in isolated adult cardiac myocytes. When V1A receptor transgene was induced to be expressed in adult mice (V1A-TG Ind ), left ventricular dysfunction and dilatation were also seen, albeit at a later time point. Because the V1A receptor mediates cell signaling through G␣ q protein, we blocked G␣ q signaling by crossing tetracycline-transactivating factor/V1A mice with transgenic mice that expressed a small inhibitory peptide against G␣ q . G␣ q blockade abrogated the development of the heart failure phenotype in tetracycline-transactivating factor/V1A-TG mice. The heart failure phenotype could be reversed by administration of doxycycline. Conclusions-Our results demonstrate a role for V1A-mediated signaling in the development of heart failure and support a role for V1A blockade in the treatment of patients with elevated levels of vasopressin. (Circulation. 2011;124:572-581.)
O ver 40 years ago, it was first reported that levels of the neurohypophyseal hormone arginine vasopressin (AVP) were elevated in patients with congestive heart failure. 1 This finding was subsequently confirmed in humans 2, 3 and in animal models of chronic heart failure. 4, 5 AVP elicits a wide range of physiological effects that are mediated by 3 known G-protein-coupled 7-transmembrane-spanning vasopressin receptor subtypes: V1A, V1B, and V2. The V1A receptor is expressed in both neuronal and nonneuronal tissues, including the heart, and elicits a variety of physiological effects, including cell contraction and proliferation, stimulation of hepatic glycogenolysis, platelet aggregation, and coagulation factor release. 6, 7 The V1B receptor subtype is found predominantly in the pituitary gland, where it stimulates adrenocorticotropic hormone release. 8, 9 Both the V1A and V1B AVP receptors act through a G protein a-subunit of the G␣ q family (␣q, q11, q14, or ␣15/16) to activate phospholipase C-␤ 10 -13 and thus enhance cellular d-myo-inositol 1,4,5-trisphosphate (IP3) and calcium levels. 10, 14 By contrast, the V2 receptor subtype is localized predominantly to the kidney, where it mediates the antidiuretic effects of AVP through the heterotrimeric G protein Gs and activation of adenylyl cyclase. [15] [16] [17] Activation of adenylyl cyclase results in increased production of cAMP, activation of protein kinase A, and subsequent redistribution of specific water channels called aquaporin-2 from intracellular vesicles to the apical plasma membrane of cells of the renal collecting ducts. 18 
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Although the pathways responsible for AVP signaling have been described, the role of AVP in the heart remains unclear. Physiologically relevant concentrations of AVP depressed cardiac function in conscious dogs, 19 elicited a biphasic hemodynamic response in isolated Langendorff-perfused rat hearts, 20 and reduced the weight of the right ventricle in an aortocaval fistula model of heart failure, but V1 antagonism did not have any effects. 21 The administration of a V1A receptor antagonist had no effect on contractility in pigs with pacing-induced heart failure, 22 whereas the chronic administration of a V1A antagonist prevented the development of heart failure but not the development of left ventricular hypertrophy in a rodent model of heart failure after myocardial infarction. 23 Low-dose infusion of AVP during ischemiareperfusion in mice increased mortality and significantly depressed myocardial function. 24 Administration of AVP to neonatal mouse cardiomyocytes elicited an increase in cell hypertrophy but not in mice in which the V1A receptor had been ablated. 25 V1A knockout mice have a normal cardiac phenotype 26 but develop less hypertrophy after transaortic constriction than do wild-type controls. 25 The disparate effects of exogenously administered AVP on the heart are due in large part to the confounding effects of AVP on the coronary and peripheral vasculature.
It has become increasingly important to understand the effects of AVP on the cardiac myocyte because of the development and the approval of both selective (V2) and nonselective (V1/V2) vasopressin antagonists for the treatment of patients with euvolemic and hypervolemic hyponatremia. We therefore created transgenic mice with controlled overexpression of the human V1A receptor. This allowed us to identify the effects of V1A activation in vivo without the confounding effects on the coronary or peripheral vasculature or on hepatic metabolism. Mice with cardiac-restricted and either constitutive or controlled overexpression of the V1A receptor demonstrated left ventricular hypertrophy, dilatation, diminished contractile performance, and reprogramming of gene expression. The myocardial effects of V1A overexpression were abrogated by turning off the V1A transgene shortly after birth or after the development of the heart failure Figure 1 . A, Schematic of the 2-component transgenic system to induce cardiac V1A receptor (V1A-R) expression. ␣MHC indicates ␣-myosin heavy chain; tTA, tetracycline-transactivating factor; and TetO, bacterial tetracycline operator. B, Echocardiography was performed on high-expression V1A receptor transgenic (V1A-TG) line (S13, V1A Hi), low-expression line (S10, V1A Low), and FVB wild-type (WT) mice at indicated ages. Fractional shortening percentage is shown. Samples were analyzed by exact Wilcoxon test, with results shown in the Table. *Adjusted PϽ0.001 vs WT; #adjusted PϽ0.05 vs V1A-low. C, Whole-heart images and picrosirius red staining of WT and V1A-TG mouse hearts at 24 weeks of age. Five-micrometer paraffin-embedded heart cross sections were stained with picrosirius red and quantified digitally. Representatives of 200ϫ magnified fields are shown. Five images from 2 WT mice and 8 images from 3 V1A-TG mice were quantified. Samples were analyzed by exact Wilcoxon test, shown in the Table. D, Atrial natriuretic peptide (ANP) gene expression in the hearts of WT and V1A-TG mice. Total ventricular mRNA extracts from 24-week-old male mice were used for real-time polymerase chain reaction, and signals were normalized to GAPDH expression in WT. *PϽ0.001 vs WT. phenotype and by genetic inhibition of G␣ q/11 signaling. Mice overexpressing the V1A receptor provide a novel model in which to study left ventricular dysfunction.
Methods

V1A Receptor Transgenic Mouse Generation
The human AVP V1A receptor cDNA was cloned into a cardiacspecific and inducible controlled vector (TREMHC) composed of a modified mouse ␣-myosin heavy chain minimal promoter fused with nucleotide binding sites for tetracycline-transactivating factor (tTA). 27 To induce transgene expression, V1A receptor transgenic (V1A-TG) mice in an FVB background were crossed with mice that expressed tTA in the heart (MHC-tTA; Figure 1A ). Because crossings of double or triple transgenes were required for gene expression, we used multiple control mice for our experiments. Where possible, these consisted of nontransgenic littermates. In the case of multiple crosses using homozygous parental lines (eg, tTA ϩ/ϩ crossing V1A ϩ/ϩ ), we assessed the phenotype in age-matched and cohabitating mice expressing the parental single transgene, as seen in Tables  1 through 4 . Detailed methods are included in the online-only Data Supplement.
Generation and Maintenance of tTA/V1A Receptor Transgenic Mouse Lines That Coexpress G␣ q Inhibitor, Gq-I Transgenic mice that overexpressed a peptide derived from a carboxyl-terminal peptide of the ␣-subunit G␣ q (Gq-I TG) were described previously. 28 The tTA/V1A/Gq-I triple-transgenic mice and their littermates in a 75% FVB/25% C57/B6 strain background were used for analysis. All protocols were approved by the Institutional Animal Care and Use Committee of Thomas Jefferson University. Detailed methods are included in the online-only Data Supplement.
Echocardiography
Echocardiography studies were performed with an ultrasonographic system (ACUSON Sequoia C256). More detailed methods may be found in the online-only Data Supplement.
Real-Time Quantitative Polymerase Chain Reaction
Real-time quantitative polymerase chain reaction analysis determined gene expression. Briefly, reverse-transcribed cDNA from myocardial RNA was used to determine gene expression. Real-time polymerase chain reaction was performed in a 50-L reaction (5 L of cDNA or 40 ng of genomic DNA with 250 nmol/L of each primer and 1ϫ SYBR Green Master Mix). Each group of experiments were performed in triplicate. The ⌬CT method with GAPDH as a reference gene was used to quantify the results and perform statistical analysis. Detailed methods can be found in the online-only Data Supplement.
Histopathology of Myocardium
Detailed methods can be found in the online-only Data Supplement.
Hemodynamic Analysis of Cardiac Function
Isolation of Adult Murine Cardiac Myocytes
Cardiac myocytes were isolated from the septum and left ventricular free wall of wild-type (WT) and V1A-TG mice. Detailed methods can be found in the online-only Data Supplement.
Contraction and [Ca
2؉ ] i Transient Measurements
Action Potential Measurements
Action potentials were recorded by current-clamp configuration at 1.5ϫ threshold stimulus and 4-ms duration. Detailed methods can be found in the online-only Data Supplement. 
Immunoblots
Immunoblotting of ventricular protein extracts was detected digitally as described previously. 29 More detailed methods can be found in the online-only Data Supplement. 
IP3 Surrogate, IP1, in Adult Myocytes
Statistical Analysis
For experiments with small sample sizes, exact nonparametric tests were used. For these experiments, summary statistics reported include the median and interquartile range, which represents the 25th to 75th percentiles. Graphically, box plots were used to visualize the range of data, and these were overlaid with individual points. For uptake experiments, sufficient sample size allowed for a 2-way ANOVA followed by post hoc group comparisons within each level of concentration. 
Results
We generated human V1A receptor transgenic (V1A-TG) mice controlled by an inducible cardiac-specific promoter with binding sites for tTA. Gene expression was initiated by crossing 5 founder V1A-TG lines with mice that expressed tTA in the heart (MHC-tTA; Figure 1A ). Using real-time polymerase chain reaction, we found 2 of the founder lines had 60 times more V1A receptor mRNA expression than WT FVB mice (lines S11 and S13; online-only Data Supplement Figure I and data not shown), and 3 of the founder lines expressed V1A receptor mRNA at levels similar to WT FVB (S1, S10, and S12; data not shown).
We followed 1 high-expression line (S13) and 1 low-expression line (S10) for more than 30 weeks by echocardiography and found at 8 weeks of age that neither V1A-TG mouse line displayed changes in cardiac function compared with WT control mice ( Figure 1B ; Table 1 ). By 24 weeks of age, the high-expression V1A-TG line but not the low-expression line had decreased cardiac function, increased heart weight-body Tables 1 and 2) . Similarly, the other high-expression line, S11, also developed cardiomyopathy by 24 weeks of age (data not shown). We used the S13 line for the remaining studies.
In a separate group of experiments, female mice were treated with doxycycline throughout pregnancy and during the postpartum period to ensure that transgene expression was suppressed during the neonatal period. At 3 to 4 weeks of age, doxycycline was removed from transgenic pups to induce V1A expression. Mature mice that were induced to express the V1A transgene (V1A-TG Ind ) still demonstrated a significant decrease in fractional shortening ( Figure 2 ) compared with control mice; however, the diminution in ventricular function in V1A-TG Ind mice was less robust than that seen in mice with constitutive overexpression of the transgene (V1A-TG) and was evident at a later point in time (35 weeks of age). For that reason, we used mice with constitutive overexpression in our subsequent experiments.
Hemodynamic Response in 24-Week-Old V1A-TG Mice
Because vasopressin is known to mediate vasoconstriction, we evaluated aortic blood pressure in 24-week-old V1A-TG mice using a 1.4F micromanometer catheter and found that both WT and V1A-TG mice had similar systolic and diastolic aortic blood pressures ( Figure 3A ), which supports our finding that V1A receptor overexpression did not occur in the vasculature. Catheter-based in vivo hemodynamic measurements showed that chronic overexpression of the V1A receptor in the heart significantly reduced hemodynamic response to the adrenergic receptor agonist isoproterenol compared with WT mice (Figures 3B and 3C ). Complete cardiac hemodynamic parameters are shown in Table 3 .
Effects of Induced V1A Receptor Overexpression on Myocyte Contraction, [Ca
2؉ ] i Transients, and Action Potential
In both WT and V1A myocytes, elevation of extracellular calcium ([Ca 2ϩ ] o ) resulted in the expected increase in contraction amplitudes; however, compared with WT myocytes, sarcoplasmic reticulum Ca 2ϩ uptake appeared to be slower in V1A-TG myocytes. Also, action potential amplitude was significantly lower in V1A-TG myocytes (PϽ0.037). The most dramatic finding was a 3.5-fold prolongation of action potential duration at 90% repolarization (APD 90 ) in V1A myocytes (PϽ0.0001). A complete description of these findings can be found in the online-only Data Supplement and supplemental Figures II and III.
Blocking of V1A Receptor Expression Reversed V1A-TG Cardiomyopathy
We previously determined that the tTA-regulated promoter could be inhibited by the stable tetracycline analog doxycycline when used at 300 mg per 1 kg of mouse chow. 30 To determine whether the cardiomyopathy induced by V1A receptor overexpression was reversible, V1A-TG mice were fed doxycycline diets at 3 weeks of age to inhibit V1A receptor transgene expression ( Figure 4A ). Cardiac function was assessed when mice reached 24 weeks of age. The discontinuation of transgene expression at puberty was sufficient to prevent the development of left ventricular hypertrophy and failure ( Figures 4B and 4C ). To determine whether the pathology induced by V1A receptor overexpression after 24 weeks of age could be reversed, we added doxycycline to the diets of V1A-TG mice and WT mice at 24 weeks of age ( Figure 4D ). After only 4 weeks on doxycycline diets (to inhibit V1A receptor transgene expression), V1A-TG mice (with confirmed reduced cardiac function at 24 weeks of age) demonstrated a significant improvement in left ventricular function and ventricular weight-body weight ratio ( Figures  4E and F) . In addition, 4 weeks of doxycycline treatment also normalized the levels of expression of atrial natriuretic peptide (data not shown), which indicates that the cardiomyopathy in this model was largely reversible.
V1A Receptor Overexpression Enhanced Insulin-Mediated Extracellular Signal-Regulated Kinase-1/2 Phosphorylation
Previous cell culture studies demonstrated that the V1A receptor signals, in part, through activation of the mitogenactivated protein kinases extracellular signal-regulated kinase-1 and -2 (Erk1/2). 25 To assess the effects of V1A receptor overexpression on Erk1/2 activation in vivo, 7-weekold V1A-TG (which had a normal cardiac phenotype) and WT mice were deprived of food overnight to stabilize baseline Erk1/2 signaling. Subsequent analysis of cardiac extracts demonstrated a significant elevation in Erk1/2 phosphorylation ( Figure 5A ). The effect of V1A receptor overexpression on Erk1/2 phosphorylation was kinase specific, because V1A-TG mice did not show a change in baseline Akt phosphorylation ( Figure 5A ) or Jun N-terminal kinase (JNK) phosphorylation (data not shown). To further confirm that V1A-TG mice did not have alterations in Akt activation, cardiac Akt was activated by intraperitoneal injection of mice with insulin (0.4 mg/kg for 15 minutes). Figure 5A shows that Akt was activated to a similar degree in both WT and V1A-TG mice after insulin injection. We also measured insulin activation in older mice (30 to 40 weeks of age). Consistent with the results in younger mice, V1A receptor overexpression did not affect Akt phosphorylation ( Figure 5B ).
G␣ q/11 Is Required for V1A Receptor-Mediated Myopathy
The V1A receptor mediates at least some of its downstream effects by coupling with the G␣ q proteins. 10, 14 To test whether V1A receptor-mediated cardiomyopathy was dependent on G␣ q signaling, we created transgenic mice that overexpressed both the V1A receptor and a peptide derived from the carboxyl-terminal end of G␣ q that inhibits G␣ q/11 signaling V1A receptor overexpression on extracellular signalregulated (Erk) 1/2 activation in the heart. A, Seven-week-old male wild-type (WT) and V1A receptor transgenic (V1A) mice were injected with insulin (0.4 mg/kg body weight, 15 minutes), and ventricular extracts were prepared. Immunoblots show phosphorylated Erk1/2 (P-Erk1/2), phosphorylated Akt (P-Akt, Thr308), and GAPDH. Graph shows GAPDH-normalized p-ERK1/2 level. *PϽ0.01 vs WT-baseline, #PϽ0.001 vs WT-insulin. Table showing median and interquartile ranges and probability values is included in the online-only Data Supplement. B, 30-to 40-week-old WT and V1A mice were simulated with insulin injection, and ventricular extracts were probed for P-Erk1/2 and P-Akt. Immunoblots of P-Akt and GAPDH are shown.
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(Gq-I) 28 ( Figure 6A ). We assessed Erk1/2 activation in the triple-transgenic mice and their littermates at 7 weeks of age. Figure 6B shows that Gq-I coexpression reduced insulinstimulated Erk1/2 phosphorylation. To determine phenotype, triple-transgenic mice and their littermates were studied at 24 weeks of age. As seen in Figures 6C and 6D and Tables 3 and 4, mice that expressed both V1A receptor and Gq-I transgenes had significantly better echocardiographic physiological parameters and hemodynamic responses than controls, which suggests that inhibition of cardiac G␣ q signaling blocked V1A receptor-induced cardiomyopathy.
Enhanced G␣ q and IP3 Signaling in Adult Myocytes Overexpressing V1A Receptor
Because the V1A receptor-G␣ q complex activates phospholipase C and induces IP3 and calcium release, we isolated adult myocytes to determine functional coupling of V1A-TG myocytes to IP3 production. We used the IP1 surrogate assay to determine the regulation of IP3 production, because IP3 production is highly transient, but its IP1 metabolite stably accumulates in LiCl-treated cells. Thus, IP1 measurement is a validated surrogate measure for ligand-induced IP3 and calcium production in cell lines expressing V1A and V1B receptors. 31, 32 To determine IP1 production in cardiac myocytes, adult cardiac myocytes from WT mice were cultured in the presence of 50 mmol/L LiCl and stimulated with insulintransferrin-selenium (which contained 10 g/mL insulin), 0.5 mol/L vasopressin, or 1 mol/L isoproterenol for 30 minutes. Vasopressin induced a 15.3-fold increase in IP1 production compared with unstimulated control myocytes. To determine IP1 production in V1A-TG myocytes, myocytes from 21-week-old V1A-TG mice were cultured in the presence of 50 mmol/L LiCl and stimulated without or with 0.5 mol/L vasopressin for 30 minutes. Myocytes from V1A-TG mice had a 2.2-fold increase in IP1 levels compared with myocytes from WT control mice (PϽ0.001). Furthermore, whereas vasopressin stimulated the IP1 level in WT myocytes by 15.3-fold, vasopressin could hyperstimulate IP1 by 29.0-fold (PϽ0.001) in myocytes from V1A-TG mice, which suggests that V1A-R overexpression in the heart enhanced IP3 signaling and that the protein expressed by the V1A transgene is physiologically linked to the endogenous V1A signaling pathway (online-only Data Supplement Figures IV and V).
Discussion
Mice with constitutive or controlled overexpression of the AVP V1A receptor in the heart showed a normal cardiac phenotype at 8 to 10 weeks of age; however, by 24 weeks of age, the hearts of mice constitutively overexpressing the V1A receptor were significantly dilated and hypertrophied and demonstrated reduced cardiac function. Mice with induced overexpression also developed LV dysfunction, albeit at 35 weeks of age. In addition, cardiac gene expression was reprogrammed, as evidenced by an increase in the expression of atrial natriuretic peptide and brain natriuretic peptide. Adult cardiac myocytes isolated from these mice showed lower systolic [Ca 2ϩ ]i, lower maximal contraction amplitudes, and reduced sarcoplasmic reticulum Ca 2ϩ -uptake activity, consistent with previous studies using AVP. The characteristic heart failure phenotype seen in the mice overexpressing the V1A receptor was elicited through activation of the G␣ q / 11 -mediated signaling cascade, because genetic ablation of the G␣ q / 11 signaling attenuated the myocardial effects of V1A receptor overexpression. In addition, the late development of the V1A-related heart failure phenotype could be abrogated by "turning off" the V1A receptor transgene shortly after birth, whereas the phenotype could be "reversed" by turning off the transgene in 24-week-old mice that had already developed ventricular dilation, diminished left ventricular function, and reprogramming of cardiac gene expression.
The use of an ␣-myosin heavy chain-driven and doxycycline-modulated transgene to increase V1A-dependent signaling in the heart provides several unique opportunities. ␣MHC indicates ␣-myosin heavy chain; TetO, bacterial tetracycline operator. B, Seven-week-old V1A-TG and V1A/Gq-I-transgenic (tTA/V1A/Gq-I) mice were simulated with insulin injection, and ventricular extracts were probed for phosphorylated Erk1/2 (P-Erk1/2). Immunoblots show P-Erk1/2 and GAPDH. Graph shows GAPDH-normalized P-Erk1/2. #PϽ0.05 vs tTA/V1A. C, Assessment of cardiac function of 24-week-old wild-type (WT), V1A-TG, and V1A/Gq-I TG mice. FS indicates fractional shortening. #Adjusted PϽ0.001 vs V1A-TG. D, Ventricular weight-body weight (VW/BW) ratio of 24-week-old WT, V1A-TG, and V1A/ Gq-I TG mice. #Adjusted PϽ0.001 vs V1A-TG. Table showing median and interquartile ranges and probability values is included in the online-only Data Supplement.
Vasoconstriction is a common consequence of pharmacological activation of AVP. Indeed, both V1A receptors and a number of other G␣ q -coupled receptors elicit vasoconstriction. 33 Thus, driving V1A overexpression using the ␣-myosin heavy chain promoter facilitates the ability to assess the effects of V1A signaling in the heart without the vasoconstriction that occurs with the exogenous administration of vasopressin or V1A-selective agonists and obviates the potential confounding effects of agonists or antagonists that do not have complete selectivity.
The bitransgenic doxycycline-regulated system also provides the opportunity to turn off transgene expression during prenatal and perinatal development, as well as during postnatal overexpression. This is relevant to the study of cellsurface receptors such as V1A that couple to G␣ q . Previous studies have shown that constitutive overexpression of G␣ q driven by the ␣-myosin heavy chain promoter results in the development of hypertrophy and many of the characteristics of pressure overload 34, 35 ; however, the effects of G␣ q overexpression with an inducible bitransgenic system in transgenic mice or adenoviral infection in cardiomyocytes are less clear. 36 -38 Indeed, Syed and coworkers 38 were unable to identify a heart failure phenotype in mice with adult-onset overexpression of G␣ q . By contrast, we found that induced overexpression begun at 3 weeks of age resulted in the development of cardiac hypertrophy, dilation, and diminished left ventricular function similar to but less than that seen with constitutive overexpression. We then asked a closely related but somewhat different question: Could prenatal and early postnatal perinatal overexpression alone elicit the development of a heart failure phenotype? To address this question, we stopped V1A transgene expression at the conclusion of the perinatal period. This experiment demonstrated that overexpression of the V1A receptor during the perinatal period alone was not sufficient to elicit a change in the cardiac phenotype.
Finally, the use of the controlled transgene allowed us to evaluated the "reversibility" of the heart failure phenotype in 24-week-old mice, a time point at which the transgenic mice overexpressing the V1A transgene demonstrated left ventricular hypertrophy and dilatation, decreased ventricular function, and reexpression of the fetal gene program, as evidenced by increased levels of atrial natriuretic factor and brain natriuretic peptide but no significant decrease in the expression of the Ca 2ϩ -ATPase. We found that discontinuation of V1A overexpression at 24 weeks resulted in a reversal in the abnormalities in fractional shortening and ventricular weightbody weight ratio, as well as normalization of the levels of expression of atrial natriuretic peptide and brain natriuretic peptide when measured 4 weeks after discontinuation of gene expression. A reversal of the heart failure phenotype has not been reported previously with other heart failure models secondary to overexpression of G-protein-coupled 7-transmembrane-spanning sarcolemmal receptors. This may be primarily because until recently, transgenic mouse models were constructed by constitutively driving the ␣-myosin heavy chain promoter rather than by use of inducible bitransgenic systems. The present finding that the heart failure phenotype can be reversed when transgene expression is interrupted is consistent with the finding that the hypertrophy and left ventricular dysfunction found in mice with controlled overexpression of G␣ q can be improved significantly after termination of the G␣ q signal, even in animals with overt heart failure. 39 Thus, the present results may be generalized to other heart failure models that are mediated through activation of G-protein-coupled receptors.
The results of the present study are consistent with findings in G␣ q transgenic mice that demonstrate hypertrophy, decreased ventricular function, loss of responsiveness to ␤-adrenergic receptor stimulation, and induction of a classic hypertrophy gene expression profile 34 ; however, there are elements of V1A receptor overexpression that are unique. For example, Akt is thought to play an important role in the heart failure phenotype in some models of G␣ q signaling. Overexpression of the WT G q results in an increase in the phosphorylation of Akt, whereas overexpression of a constitutively active G␣ q subunit markedly attenuates Akt phosphorylation and results in significant apoptosis and early mortality. 40, 41 Akt is also a major downstream target of the phosphatidylinositol 3-kinase involved in angiotensin II-induced proliferation of vascular smooth muscle. 42 By contrast, overexpres- Echocardiography of V1A TG mice and control mice at 24 wk of age. FS%, percent fractional shortening; LVEDD, LV end-diastolic dimension in mm; LVESD, LV end-systolic dimension in mm. tTA/V1A was tested against GqI/V1A, tTa/GqI, and tTA/V1A/GqI combined. P-Valuess for FS%, LVEDD, LVESD, and Heart Rate were Ͻ0.0001, Ͻ0.0001, Ͻ0.0001, and 0.1703, respectively. sion of V1A receptors did not influence Akt phosphorylation in the present experiments.
Another important difference between the V1A-TG mice and heart failure models created by overexpression of G␣ q is the time course of the development of the heart failure phenotype. Constitutive 5-fold overexpression of G␣ q effected the development of a heart failure phenotype by 8 weeks of age in transgenic mouse models 35, 43 ; however, overexpression of the V1A receptor took 24 weeks to illicit a change in the cardiac phenotype. This delay in the development of the heart failure phenotype was similar to that seen with overexpression of the ␤ 1 -adrenergic receptor, albeit at a substantially lower level of V1A expression. 44 Comparison to signaling of angiotensin II type 1 receptor can be found in the online-only Data Supplement.
Mice with gene ablation of V1A receptor demonstrated altered cardiovascular hemodynamics and lower basal blood pressure. 26, 45 AVP failed to induce vasoconstrictive responses in mice that lacked the V1A receptor. In addition, arterial baroreceptor reflexes were markedly impaired because of loss of V1A receptors in baroreflex neurons. The present finding that blood pressure was unchanged in mice overexpressing the V1A receptor was disparate from the earlier studies but reflected the fact that the V1A receptor was only overexpressed in cardiac muscle and not in the smooth muscle underlying the peripheral or coronary vasculature.
That overexpression of the V1A receptor in FVB mice is physiologically coupled to the downstream signaling pathways that are known to be activated by vasopressin was demonstrated by the fact that myocytes isolated from V1A-TG hearts showed significant activation of IP3, as measured by IP1 accumulation compared with controls. IP3 is a well-established primary signaling pathway for vasopressin. 10, 31, 32 The finding that chronic overexpression of the V1A receptor resulted in the development of cardiac hypertrophy, dilatation, and diminished left ventricular function may have clinical relevance. The administration of the V2-selective vasopressin antagonist tolvaptan increased serum [Na 2ϩ ] in patients with hypervolemic hyponatremia secondary to congestive heart failure but did not improve survival. 46 The present results suggest that the combining of V1A and V2 receptor antagonists may have a more robust effect on myocardial function than the use of a V2 receptor antagonist alone and that V1A-selective vasopressin antagonists may be useful in the treatment of patients with heart failure and elevated levels of vasopressin. 
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CLINICAL PERSPECTIVE
Heart failure is associated with an increase in circulating levels of arginine vasopressin (AVP). AVP activates vasopressin V2 receptors in the kidney, which results in redistribution of aquaporin-2 water channels and the reabsorption of free water. This results in the development of edema and hyponatremia. Selective antagonism of the V2-selective vasopressin receptor significantly increases serum sodium levels and removes free water in patients with heart failure. AVP also interacts with vasopressin V1A receptors in the heart; however, the effects of AVP on the heart muscle are not well understood. In the present study, we found that cardiac-specific overexpression of the vasopressin V1A receptor caused the development of heart failure in transgenic mice. The vasopressin V1A receptor-mediated development of heart failure was reversed by "turning off" the overexpression of the transgene or by blocking a G-protein-dependent signaling pathway, Gq, downstream of the V1A receptor. These results, albeit in a mouse model, suggest that a V1A receptor antagonist or inhibition of the Gq signaling pathway may be useful adjuncts to vasopressin V2 receptor antagonism in the treatment of patients with heart failure. have shown that this inducible system has no effect on cardiac function, most likely due to the fortuitous use of a bacterially derived tTA construct in which the less than ideal usage of bacterial codon in a mammalian system resulted in multiple aberrant splice sites and less than 1% of the bacterial V1A cDNA encoded the full-length protein. As a result, the very low level expression of bacterial tTA does not affect mouse cardiac functions, but is sufficient to induce robust expression of transgenes in double transgenic mice expressing both bacterial tTA transgene and various responder genes, including GSK3, adenosine A 1 receptor, adenosine A 2A receptor, G q and NCX [1] [2] [3] [4] [5] . To prevent phenotype selection due to line propagation, the strains were propagated in the absence of inducer transgene, tTA. To induce transgene expression, V1A receptor transgenic (V1A-TG) mice in FVB background were crossed with mice that expressed tTA in the heart (MHC-tTA) (Fig. 1A in the main text) . In this "tet-off" inducible system, the stable tetracycline ana doxycycline, inhibits tTA transactivation. To inhibit transgene expression, mouse diets containing 300mg DOX/kg (Bio-Serv, NJ) were administered for the time periods indicated in the experiments.
SUPPLEMENTAL MATERIAL
Controlled and
Since crossings of double or triple transgenes were required for gene expression, we used multiple control mice for our experiments. Where possible, these consisted of non-transgenic littermates. In case of multiple crosses using homozygous parental lines (eg. tTA+/+ crossing V1A+/+), we assessed the phenotype in age matched and co-habitating mice expressing the parental single transgene as see Table 1 and Table 3 250 nM each primer; 1X SYBRE Green Master Mix). Each experimental group was performed in triplicate. The CT method using GAPDH as reference gene was used to quantify the results and perform statistic analysis as suggested 7, 8 . Since small sample sizes were used in real-time PCR experiments, non-parametric alternative to the t-test (Mann-Whitney test) was used to test statistical significance. CT values were then converted to fold changes in gene expression relative to WT samples as described Histopathology of Myocardium. 5µm sections of fixed tissue were stained with Picrosirius Red for assessment of fibrosis (Research Animal Diagnostic Laboratory, University of Missouri). To determine fibrosis, independent high-power fields of stained images were digitally photographed using identical exposure times and incident light intensities and analyzed using Image J system (NIH 1.42 Version software) as described 9, 10 . The data were reported as arbitrary units.
Hemodynamic Analysis of Cardiac Function. For in vivo hemodynamic measurements, a 1.4
French micromanometer-tipped catheter (SPR-671; Millar Instruments Inc.) was inserted into the right carotid artery and advanced into the LV of mice that were lightly anesthetized (i.e., maintained spontaneous respirations) with tribromoethanol/amylene hydrate (2.5% wt/vol, 8 μl/g injected intraperitoneal; Avertin). Hemodynamic parameters, including heart rate, LV end-diastolic pressure, and +dP/dt and -dP/dt, were recorded in closed-chest mode, both at baseline and in response to isoproterenol (10 ng), administered via cannulation of the right internal jugular vein 11 .
Isolation of Adult Murine Cardiac Myocytes. Cardiac myocytes were isolated from the septum and LV free wall of WT and V1A-TG mice as previously described 12, 13 . Briefly, excised hearts were mounted on a steel cannula and retrograde perfused (100 cm H 2 O, 37°C) with Ca ] i transient measurements were performed as previously described 12, 13 . Action Potential Measurements. Action potentials were recorded using current-clamp configuration at 1.5x threshold stimulus and 4-ms duration 14, 15 . Pipette solution consisted of (in mM): 125 KCl, 4 
Immunoblots.
Immunoblotting of ventricular protein extracts was digitally detected as described 3 .
Briefly, frozen ventricular tissues were homogenized on ice using a non-ionic detergent-based lysis buffer (25mM Tris-HCl pH 7.6, 137mM NaCl, 10% glycerol, 1% NP40 or IGEPAL CA-630, 10mM NaF) freshly supplemented with 1mM sodium pyrophosphate, 5µg/ml leupeptin, 5µg/ml aprotinin, 1mM EDTA, 10mM PMSF, and 1mM NaVO4. Proteins were separated by SDS-PAGE (4-12%) and transferred onto nitrocellulose membranes. The following antibodies were used: rabbit anti-phosphoErk1/2, rabbit anti-phospho-Akt Thr308 (Cell Signaling Tech., Beverly, MA) and anti-GAPDH Resting membrane potential and action potential duration at 50% repolarization (APD 50 ) were similar between WT and V1A myocytes (Sup. Fig. 3 and Sup. Table 2 ). But action potential ampli (P<0.037) was significantly lower in V1A-TG myocytes. The most dramatic finding is a 3.5-fold prolongation of action poten Supplemental Discussion:
C rison to signaling of angiotensin II type 1 receptor
The angiotensin II type 1 receptor is another G protein-coupled cell surface receptor that mediates cardiac hypertrophy through Gα q ; however, unlike the V1A receptor, the angiotensin type 1 receptor also couples to Gα i thereby regulating adenylyl cyclase 18, 19 . 20, 21 . We found that inhibition of Gα q/11 alone could attenuate the development of hypertrophy, dilatation and failure in the myocardium of mice over-expressing the V1A receptor, suggesting that the myocardial effects of V1A signaling are mediate through Gα q/11 alone. Our finding that V1A signaling through Gα q/11 differs from signaling with o 
